51st week of 2014 patent applcation highlights part 51 |
Patent application number | Title | Published |
20140371248 | SMALL MOLECULE ACTIVATORS OF HslV PROTEASE FOR DEVELOPMENT OF NOVEL ANTIMICROBIALS - HslVU is the proteasome-related system composed of HslV peptidase and HslU chaperone. It is involved in intracellular proteolysis. The presence of HslVU homologs in pathogenic microbes and its absence in human makes it an antimicrobial drug target. The functional HslVU complex forms when HslV dodecamer is flanked at both ends by HslU hexamers. In the HslVU complex, intercalation of C-termini residues of HslU subunits into the clefts between adjacent HslV subunits results in allosteric activation of HslV. We identified small molecules capable of activating HslV peptidase in the absence of its natural activator HslU. Quinazoline and chromone derivatives were suggested by ligand docking to bind at the HslU C-termini intercalation pockets in the HslV. This was confirmed by HslV activation assays with these compounds that gave ED | 2014-12-18 |
20140371249 | CRYSTAL OF A FREE TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE - To provide a crystal of a tricyclic pyrazolopyrimidine compound inhibiting the effect of HSP90. The present invention provides a crystal of 2-{4-amino-2-[(3-chloro-4-methoxy-5-methylpyridin-2-yl)methyl]-2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo[cd]azulen-8-yl}-N-methylacetamide which inhibits the ATPase activity of HSP90 and which has antitumor activity, a medicament comprising the same, an anticancer agent comprising the same, and the like. | 2014-12-18 |
20140371250 | Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors - The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to rheumatoid arthritis. | 2014-12-18 |
20140371251 | METHOD OF INHIBITING DYRK1B - The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened. | 2014-12-18 |
20140371252 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS - Processes for making and using compounds of formula (I): | 2014-12-18 |
20140371253 | Cyclopamine Analogs - The invention provides novel derivatives of cyclopamine having the following formula: | 2014-12-18 |
20140371254 | NOVEL TREATMENT OF GEFITINIB-RESISTANT NON-SMALL-CELL LUNG CANCER - The present invention discloses a method of preventing and treating Gefitinib-resistant non-small-cell lung cancer, comprising administering an effective amount of an alkaloid. A pharmaceutical composition comprising an alkaloid admixed with a pharmaceutical carrier for treating Gefitinib-resistant non-small-cell lung cancer is also disclosed therein. | 2014-12-18 |
20140371256 | PERSONALIZED PAIN MANAGEMENT AND ANESTHESIA: PREEMPTIVE RISK IDENTIFICATION AND THERAPEUTIC DECISION SUPPORT - Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids. Therefore, patients who are genetically predisposed to risk of inadequate pain relief and/or serious side effects from anesthesia, analgesics, and/or opioids can be identified and individualized treatment plans developed for implementation by the clinician to improve clinical and economic outcomes. | 2014-12-18 |
20140371257 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2014-12-18 |
20140371258 | Water-Soluble Polymer Conjugates of Topotecan - Provided herein are water-soluble polymer conjugates of topotecan, along with compositions comprising the conjugates and related methods of making and using the same. | 2014-12-18 |
20140371259 | COMPOUNDS AND METHODS FOR INHIBITION OF AP ENDONUCLEASE-1/REDOX FACTOR-1 (HAPE1) ACTIVITY - A method for treating a neoplasm in a subject, comprising co-administering to the subject a therapeutically effective amount of an anticancer agent and a substituted 6,7-methylenedioxy-4-amino-quinoline, or a pharmaceutically acceptable salt or ester thereof. | 2014-12-18 |
20140371260 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS - The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine. | 2014-12-18 |
20140371261 | INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER - Provided are compositions for inhibiting a biological activity of an aldoketo reductase family 1, member C3 (AKR1 C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1 C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects. | 2014-12-18 |
20140371262 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR THROMBOEMBOLISM IN THROMBOEMBOLISM PATIENT WITH SEVERE RENAL IMPAIRMENT - It is intended to provide a highly safe, orally administrable preventive and/or therapeutic agent for thrombosis and/or embolism that can be applied to a thrombosis and/or embolism patient with severe renal impairment. The present inventors have found that even for a thrombosis and/or embolism patient with severe renal impairment, use of edoxaban at a dose of 15 mg once a day can effectively prevent thrombosis and/or embolism while avoiding the risk of bleeding. The present inventors have also found that even for a thrombosis and/or embolism patient with severe renal impairment, edoxaban at a dose of 15 mg once a day can effectively prevent thrombosis and/or embolism with safety over a long period. | 2014-12-18 |
20140371263 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS - The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof: | 2014-12-18 |
20140371264 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS - Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. | 2014-12-18 |
20140371265 | COMPOSITIONS AND METHODS FOR TREATMENT - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 2014-12-18 |
20140371266 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors - Provided are monoquaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and gastrointestinal tract disorders. | 2014-12-18 |
20140371267 | OPHTHALMIC COMPOSITION WITH NITRIC OXIDE DONOR COMPOUND AND METHOD OF FORMING AND USING SAME - The present invention is directed to the provision of ophthalmic compositions such as multi-dose, topical, ophthalmic compositions. The compositions include a nitric oxide (NO) donor compound. | 2014-12-18 |
20140371268 | BIPHENYLCARBOXAMIDES AS ROCK KINASE INHIBITORS - The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases, gastrointestinal diseases and respiratory diseases. | 2014-12-18 |
20140371269 | PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT-2 INHIBITORS - The present invention provides compounds of Formula I or a pharmaceutical salt thereof, where the variables for R1, R2, and R3 are as described herein; methods of treating a condition such as hypertriglyceridemia; and processes for preparing the compounds. | 2014-12-18 |
20140371270 | NOVEL ACETIC ACID ESTER COMPOUND OR SALT THEREOF - An acetic acid ester compound represented by the following formula (I) or a salt thereof, | 2014-12-18 |
20140371271 | NOVEL PIPERINE DERIVATIVES AND USES THEREOF - The present invention provides novel piperine derivatives. The present pharmaceutical or food composition containing a piperine derivative as an active ingredient is very effective in preventing or treating metabolic diseases including obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome. Piperine derivatives of the present invention useful as pharmaceuticals compositions or functional food compositions has therapeutic efficacies for metabolic syndrome selected from the group consisting of obesity, diabetes, hyperlipidemia, fatty liver and insulin resistance syndrome, and also suppress the differentiation of progenitor cells and reduce the accumulation of triglycerides. | 2014-12-18 |
20140371272 | THERAPEUTIC COMPOUNDS - The invention provides compounds of formula (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula (I) and therapeutic methods for treating cancer or treating autoimmune diseases or preventing transplant rejection using compounds of formula (I). | 2014-12-18 |
20140371273 | POLYMORPHS OF PERAMPANEL - The present invention provides novel crystalline forms of perampanel, pharmaceutical compositions comprising same, methods for their preparation and uses thereof for treating seizures and epilepsy. | 2014-12-18 |
20140371274 | BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to novel compounds, their use in the prevention or treatment of symptoms and disorders associated with the bradykinin B | 2014-12-18 |
20140371275 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-- METHYLPYRIDIN-2-YL) BENZOIC ACID - The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith. | 2014-12-18 |
20140371276 | TRPM8 ANTAGONISTS - The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exhacerbated respiratory disorders and urological disorders. | 2014-12-18 |
20140371277 | COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder. | 2014-12-18 |
20140371278 | BENZOHETEROCYCLIC COMPOUNDS AND USE THEREOF - Disclosed are compound of formula (I) and pharmaceutically accepted salts and prodrugs thereof, wherein each of R | 2014-12-18 |
20140371279 | CRYSTALLINE FORMS OF AZILSARTAN AND PREPARATION AND USES THEREOF - The present invention relates to the field of pharmaceutical chemistry. Disclosed herein is a crystalline form of azilsartan, which is substantially pure. The crystalline form is crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J or form K. The substantially pure crystalline forms of azilsartan of the invention generally have good properties such as high solubility, high bioavailability, good stability, long shelf life and good antistatic property. The crystalline forms of azilsartan generally exhibit an excellent performance in reducing clinical systolic blood pressure (SBP) and average 24-hour SBP. Disclosed herein are methods of preparing the substantially pure crystalline forms of azilsartan, pharmaceutical compositions comprising the crystalline forms, and preparation methods and uses thereof. | 2014-12-18 |
20140371280 | Method of treating diabetic peripheral neuropathy through amendment of pre-neuronal diabetic coagulative micro-angiopathy and neuronal deficiency of mitochondrial ATP production, and through induction of neuronal regeneration - DPN is an intractable and tormenting neurovascular and dermal disorder. | 2014-12-18 |
20140371281 | Pesticidal Mixtures - The present invention relates to pesticidal mixtures comprising a component A and a component B, wherein component A is a compound of formula (I) wherein B | 2014-12-18 |
20140371282 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS WITH IMPROVED BIOAVAILABILILTY - The present invention provides a controlled release oral pharmaceutical composition having a therapeutically effective amount of one or more pharmacologically active agent having low bioavailability; one or more solubilizers; one or more biocompatible swelling agents; and a swelling enhancer. The swelling agent, in combination with swelling enhancer, swells in the presence of water in gastric fluid such that the size of the dosage form is sufficiently increased to provide retention of the dosage form in the stomach of a patient, which gradually erodes within the gastrointestinal tract over a prolonged time period. | 2014-12-18 |
20140371283 | HYDANTOINS THAT MODULATE BACE-MEDIATED APP PROCESSING - In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition. | 2014-12-18 |
20140371284 | IMIDAZOLIDINEDIONE COMPOUNDS AND THEIR USES - Provided are imidazolidinedione compounds of formula (I), processes for preparation, uses and pharmaceutically compositions thereof. Said imidazolidinedione compounds posses androgen receptor antagonist activity and can be used for preventing and treating diseases and disorders related to androgen receptor, such as prostate cancer, alopecia, hair regeneration, acne and adolescent acne. | 2014-12-18 |
20140371285 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE - Salinomycin analogs and pharmaceutically acceptable compositions containing salinomycin analogs. Dosage forms and kits comprising salinomycin analogs and pharmaceutically acceptable compositions containing salinomycin analogs. Methods of using salinomycin analogs, pharmaceutically acceptable compositions, dosage forms, and kits for the treatment of proliferative diseases, e.g., cancer, or microbial infections in a subject | 2014-12-18 |
20140371286 | DE NOVO SYNTHESIS OF BACTERIOCHLORINS - A method of making a bacteriochlorin is carried out by condensing a pair of compounds of Formula II | 2014-12-18 |
20140371287 | METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-ETHYLSULFONYLETHYL]-4-ACETYLAMINOIS- OINDOLINE-1,3-DIONE - Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4. | 2014-12-18 |
20140371288 | PLANT DISEASE CONTROL COMPOSITION - To provide a plant disease control composition having excellent control effect against plant diseases. | 2014-12-18 |
20140371289 | COMPOSITION FOR ELIMINATION OF TROUBLESOME VARMINTS - Composition for elimination of troublesome varmints comprises all the non-essential amino acids alanine, glycine, proline, serine, tyrosine, aspartic acid, asparagine, glutamic acid. | 2014-12-18 |
20140371290 | Glycopyrrolate Salts - Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed. | 2014-12-18 |
20140371291 | SERINE RACEMASE INHIBITOR - A novel serine racemase inhibitor exhibits sufficient activity and specificity. The serine racemase inhibitor includes one or more compounds selected from compounds respectively represented by the following general formulas [MM_1], [DR_1], [DR′_1], [LW_1], and [ED_1] as an active ingredient. | 2014-12-18 |
20140371292 | Method for the controlled intracellular delivery of nucleic acids - The present invention relates to a method for the controlled intracellular delivery of nucleic acid molecules into one or more target cells, in particular tumor cells, the method comprising: providing a polymeric complex formed between one or more nucleic acid molecules to be delivered and one or more cationic carrier molecules, wherein at least a part of the one or more carrier molecules in the polymeric complex are covalently attached to hydroxyalkyl starch, and wherein the hydroxyalkyl starch is shielding the polymeric complex; allowing the shielded polymeric complex to get into contact with the one or more target cells; deshielding the polymeric complex by removing the hydroxyalkyl starch; and allowing the deshielded polymeric complex to internalize into the one or more target cells. Removal of the hydroxyalkyl starch can be accomplished enzymatically by exposing the polymeric complex to amylase. The invention also concerns the use of such method for the prevention and/or treatment of a condition selected from the group consisting of cancer, immune diseases, cardiovascular diseases, neuronal diseases, infections, and inflammatory diseases. | 2014-12-18 |
20140371293 | Amine Cationic Lipids and Uses Thereof - The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent). | 2014-12-18 |
20140371294 | COMPOSITIONS AND METHODS COMPRISING HISTIDYL-TRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES - Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto. | 2014-12-18 |
20140371295 | METHODS AND COMPOSITIONS TO PROTECT AQUATIC INVERTEBRATES FROM DISEASE - Compositions and methods of protecting aquatic invertebrates from disease is shown. In one embodiment, dsRNA or antisense RNA to a nucleic acid molecule of the disease-causing microorganism is prepared and delivered to the animal. In another embodiment, a nucleic acid molecule of the disease-causing microorganism is delivered to the animal. In another embodiment, the RNA or nucleic acid molecule is delivered to the animal by replicon particle. In a further embodiment, the protective molecule is delivered to the digestive tract of the animal. Protection from disease is obtained. | 2014-12-18 |
20140371296 | METHODS FOR MODULATING METASTASIS-ASSOCIATED-IN-LUNG-ADENOCARCINOMA-TRANSCRIPT-1 (MALAT-1) EXPRESSION - The present embodiments provide compounds and methods for reducing expression of Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1 (MALAT-1) RNA and/or protein in an animal. Such methods are useful for treating cancer, such as colon cancer, intestinal cancer, lung cancer (e.g. non-small cell lung cancer), liver cancer, and/or prostate cancer. In various aspects, the cancer is a primary cancer. | 2014-12-18 |
20140371297 | ANTI-CONNEXIN COMPOUNDS TARGETED TO CONNEXINS AND METHODS OF USE THEREOF - Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable. | 2014-12-18 |
20140371298 | PREVENTION AND TREATMENT OF NOSEMA DISEASE IN BEES - Compositions and methods for reducing susceptibility and enhancing tolerance to | 2014-12-18 |
20140371299 | Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis - The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for down regulating pro-inflammatory cytokines in a mammal by administering siRNA against eIF-5A1 to the mammal to treat/prevent sepsis and/or hemorrhagic shock. | 2014-12-18 |
20140371300 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER - The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent. | 2014-12-18 |
20140371301 | TREATMENT OF TUMOR NECROSIS FACTOR RECEPTOR 2 (TNFR2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TNFR2 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Necrosis Factor Receptor 2 (TNFR2), in particular, by targeting natural antisense polynucleotides of Tumor Necrosis Factor Receptor 2 (TNFR2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TNFR2. | 2014-12-18 |
20140371302 | MODIFIED MRNAS ENCODING CELL-PENETRATING POLYPEPTIDES - This invention relates to modified nucleic acid compositions encoding cell-penetrating polypeptides to provoke an innate immune response in a cell and methods of delivering protein-binding partners to target cells. | 2014-12-18 |
20140371303 | COMPOSITIONS AND METHODS FOR GLYCEMIC CONTROL OF SUBJECTS WITH IMPAIRED FASTING GLUCOSE - Compositions and methods for providing anti-diabetic and anti-hyperlipidemia benefits to diabetic subjects currently on medication but not meeting recommended targets for blood glucose, HbA1c, blood pressure and total cholesterol. | 2014-12-18 |
20140371304 | METHOD FOR SUPPRESSING TUMORIGENICITY OF STEM CELLS - A method for suppressing tumorigenicity of stem cells in a mammalian subject, which comprises administering an effective amount of a fatty acid derivative and a method for suppressing tumorigenicity of stem cells of a mammalian subject, which comprises contacting said stem cell with an effective amount of a fatty acid derivative, are provided. | 2014-12-18 |
20140371305 | Mupirocin Antibiotic Composition - An antibiotic inhalation or irrigation composition for the treatment of bacterial infections especially in the respiratory tract, is provided. The antibiotic inhalation or irrigation composition may include a mixture of mupirocin as active pharmaceutical ingredient (API), and a micronized poloxamer composition as excipient. Micronized poloxamer composition may be produced by mixing poloxamer 188 and poloxamer 407 in an apparatus where a low-frequency acoustic field is applied to facilitate mixing. Antibiotic inhalation or irrigation composition may be obtained in powder or solution form. In other embodiments, antibiotic inhalation or irrigation composition may be employed to produce a topical formulation for the treatment of traumatic skin lesions. In some embodiments, other suitable poloxamers or sugar alcohols may be employed as excipients. Due to the synergistic effect of micronized poloxamer composition, antibiotic inhalation or irrigation composition may provide improved solubility and bioavailability of mupirocin, thus decreasing side effects and time of treatment. | 2014-12-18 |
20140371306 | PHARMACEUTICAL COMPOSITIONS COMPRISING LIGNANS AND THEIR DERIVATIVES FOR TREATING HYPERPLASTIC DISEASES - The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from | 2014-12-18 |
20140371307 | SIRT 1 ACTIVATOR INCLUDING SYRINGARESINOL - The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases. | 2014-12-18 |
20140371308 | HYPOTENSIVE LIPID-CONTAINING BIODEGRADABLE INTRAOCULAR IMPLANTS AND RELATED METHODS - Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma. | 2014-12-18 |
20140371309 | OPHTHALMIC SOLUTION - The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient. | 2014-12-18 |
20140371310 | MANDELIC ACID CONDENSATION POLYMERS - Disclosed herein are compounds and compositions useful for reducing the risk of infection. In particular, disclosed herein are mandelic acid condensation polymers, compositions comprising such compounds, processes for producing such compounds, and methods of using such compounds. | 2014-12-18 |
20140371311 | INGENANE-TYPE DITERPENE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING VIRAL INFECTIOUS DISEASES CONTAINING SAME - The present invention relates to an injenane-type diterpene compound derived from | 2014-12-18 |
20140371312 | COMPOSITION FOR PREVENTING THE OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT - Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient. | 2014-12-18 |
20140371313 | Cyclohexane-1,3-Diones for Use in the Treatment of Amyotrophic Lateral Sclerosis - The present invention relates to the identification of provided cyclohexane-1,3-diones (CHD compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided CHD compounds. | 2014-12-18 |
20140371314 | Deuterated Tetramethyl Dioic Acids, Compositions Comprising Them And Uses Thereof - This invention relates to deuterated tetramethyl dioic acids, compositions comprising them and uses thereof in the treatment of Metabolic Syndrome and any diseases, disorders or symptoms associated therewith. | 2014-12-18 |
20140371315 | PREPARED FOODS HAVING HIGH EFFICACY OMEGA-6/OMEGA-3 BALANCED POLYUNSATURATED FATTY ACIDS - A composition and method for supplementing food, nutrition, and diet systems with omega-6 to omega-3 balanced oils comprising a synergistic blend of at least two oils. The composition further comprises a synergistic blend of long chain omega-3 oil as a means to further increase the nutritional value. The composition provides an effective increase in therapeutic and pharmacological properties in nutrition and diet systems. | 2014-12-18 |
20140371316 | DERIVATIVES OF PHENOXYISOBUTYRIC ACID - The present invention provides a process for the synthesis of substituted phenoxymethylpropiomc acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products). | 2014-12-18 |
20140371317 | Silicone Resin Emulsions - The present disclosure relates to compositions comprising: i) an aqueous silicone emulsion comprising; A) 0.5 wt % to 95 wt % of a silicone gum, resin, or PSA, B) 0.1 to 90 wt % of an ethylene oxide/propylene oxide block copolymer, and sufficient amount of water to sum all ingredients of the silicone gum emulsion to 100 weight percent, ii) a healthcare active, and iii) an optional enhancer(s). | 2014-12-18 |
20140371318 | ORALLY-DISINTEGRATING FORMULATIONS OF FLURBIPROFEN - The present invention relates to an orally-disintegrating pharmaceutical formulation, which is characterized by comprising flurbiprofen and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. | 2014-12-18 |
20140371319 | NOVEL INDANESULFAMlDE DERIVATIVES - Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy. | 2014-12-18 |
20140371320 | COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH - Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I | 2014-12-18 |
20140371321 | NOVEL PROCESS FOR CONCENTRATING SPILANTHOL AND/OR ISOMERS AND/OR HOMOLOGUES THEREOF - A subject of the invention is a process for concentrating the spilanthol contained in a composition, comprising the formation of an addition compound of spilanthol with a strong acid, then the hydrolysis of said addition compound. | 2014-12-18 |
20140371322 | Phenoxybenzamine Transdermal Composition - A phenoxybenzamine transdermal composition for treating neuropathic pain is disclosed. The phenoxybenzamine transdermal composition may include phenoxybenzamine in a concentration of about 5 mg/g to about 120 mg/g, with about 15 mg/g being preferred, in combination with a pharmaceutically suitable permeation enhancer that may be included in amounts of about 20% by weight to about 99.95% by weight, with about 50% by weight being preferred. Permeation enhancer composition within disclosed phenoxybenzamine transdermal composition may improve penetration of phenoxybenzamine in a patient's tissue or skin. The phenoxybenzamine transdermal composition may provide a long duration blockade of sensitized pain receptors of 24 hours or more, resulting in an effective treatment for neuropathic pain with lower concentrations of phenoxybenzamine and requiring fewer applications. | 2014-12-18 |
20140371323 | FORMULATIONS COMPRISING 2-AMINO-2-[2-(4-OCTYLPHENYL)ETHYL]PROPANE-1,3-DIOL - A solid pharmaceutical composition suitable for oral administration, comprising:
| 2014-12-18 |
20140371324 | INHIBITORS OF COGNITIVE DECLINE - Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention. | 2014-12-18 |
20140371325 | NITISINONE FOR TREATMENT OF OCULOCUTANEOUS/OCULAR ALBINISM AND FOR INCREASING PIGMENTATION - A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione), also known as NTBC for a sufficient period of time. The administration of NTBC is believed to increase the amount of pigmentation in the subject and alleviate certain symptoms caused by lack of pigmentation in the eye tissues. Also described are methods of use of NTBC for increasing the pigmentation of a subject for cosmetic purposes, by administering to the subject a therapeutically effective amount of NTBC. | 2014-12-18 |
20140371326 | FOOD COMPOSITION FOR PREVENTING OBESITY, PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY, AND ANIMAL MEDICINE FOR TREATING OBESITY, CONTAINING GINGERNONE A - Disclosed is a composition comprising gingerenone A as an active ingredient. The composition includes a food composition for preventing obesity, a pharmaceutical composition for treating obesity and a medicine for treating animal obesity. Since the composition includes gingerenone A, which inhibits expression of the important transcriptional factors C/EBPα and PPARγ, expressed upon adipocyte differentiation, as well as FAS protein expression, the composition has superior potential for obesity prevention or treatment. | 2014-12-18 |
20140371327 | Formulation of Curcumin with Enhanced Bioavailability of Curcumin and method of preparation and treatment thereof - Disclosure provides a formulation of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin and to augment the biological activity of curcumin, wherein curcumin is the main constituent of curcuminoid and wherein Ar-turmerone is the main constituent of the essential oil of turmeric. An application of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin for oral supplementation against a variety of diseases and method of doing the same is provided. | 2014-12-18 |
20140371328 | NOVEL COMPOUNDS - The present invention relates to topical compositions comprising resveratrol in a liquid crystal gel network formed by a phosphate ester surfactant and a co-emulsifier. The present invention also relates to the process to make such compositions. | 2014-12-18 |
20140371329 | Buffered Oxygen Therapeutic - An oxygen therapeutic composition, which includes a perfluorocarbon material having a boiling point of about 4 degrees Celsius to about 60 degrees Celsius, a lipid; a viscosity modifier; a buffer. | 2014-12-18 |
20140371330 | Novel Co-Modified Organopolysiloxane, And Treatment Agent And External Use Preparation Comprising The Same - A co-modified organopolysiloxane having a viscosity at 25° C. of not more than 1,500 mPa·s, a group that has a siloxane dendron structure, a hydrophilic group, and expressed by the following general formula (1): R | 2014-12-18 |
20140371331 | SURFACTANT COMPOSITION - The present invention provides a surfactant composition containing a polyglycerol alkyl ether which is capable of exhibiting a high emulsification performance for silicone oils compounded in cosmetics, detergents, etc., by using a natural alcohol derived from oils and fats as a raw material thereof, a process for producing the surfactant composition in an effective manner, and a use of the surfactant composition. The present invention relates to [1] a surfactant composition including a specific polyglycerol monoalkyl ether (1) and a specific polyglycerol dialkyl ether (2), a mass ratio of [(1)/(2)] being from 65/35 to 75/25; [2] a process for producing the surfactant composition; [3] an emulsifier composition including the surfactant composition; and [4] a detergent composition including the surfactant composition. | 2014-12-18 |
20140371332 | METHOD FOR PRODUCING VESICLE COMPOSITION - Provided is a method for producing a vesicle composition having an aqueous phase as a continuous phase, containing: an oil phase-preparation step for dissolving an oil phase containing components (A) to (D) at a temperature of equal to or higher than melting point of the oil phase, the components (A) to (D) being: the component (A): a fatty acid of total carbon number of from 12 to 40; the component (B): a tertiary amine compound of total carbon number of from 8 to 75; the component (C): an organic acid of total carbon number of from 1 to 10; and the component (D): the first polyol, an emulsification step for adding the aqueous phase to the oil phase obtained in the oil phase-preparation step while being mixed; an addition step for adding a component (D′): the second polyol, after a quantity of the aqueous phase added to the oil phase is equal to or larger than 1 time by mass of a quantity of the oil phase; and cooling step for cooling the obtained composition after the emulsification step. | 2014-12-18 |
20140371333 | LECITHIN-ORGANOGELLING AGENT - An organogelling agent for forming reverse worm-like micelles having high safety to living bodies and the environment, favorable feel of use, and a high gelating ability and a thickened gel composition comprising the organogelling agent are provided. Lecithin and ascorbic acid or an ascorbic acid derivative act as an organogelling agent to form reverse worm-like micelles of a variety of oils. A thickened gel composition having a reverse worm-like micelle structure can be prepared with a ternary system of lecithin, ascorbic acid or an ascorbic acid derivative, and a variety of oils. | 2014-12-18 |
20140371334 | SLURRY PHASE APPARATUS - A method of operating a slurry phase apparatus includes feeding one or more gaseous reactants into a slurry body of solid particulate material suspended in a suspension liquid contained inside a vessel. The one or more gaseous reactants are fed into the slurry body through a gas distributor having downward facing gas outlets and are fed towards a fluid impermeable partition spanning across the vessel below the gas distributor. The partition divides the vessel into a slurry volume above the partition and a bottom volume below the partition. A differential pressure is maintained over the partition between predefined limits by manipulating or allowing changes in the pressure in the bottom volume by employing a pressure transfer passage establishing flow or pressure communication between the bottom volume and a head space above the slurry body. | 2014-12-18 |
20140371335 | EXPANDABLE GRANULATES BASED ON VINYL-AROMATIC POLYMERS HAVING AN IMPROVED EXPANDABILITY AND PROCESS FOR THE PREPARATION THEREOF - Expandable granulates, having compositions based on vinyl-aromatic polymers, including: a) 65-99.8% by weight of a copolymer obtained by polymerizing 85-100% by weight of one or more vinyl-aromatic monomers and 0-15% by weight of an α-alkylstyrene in which the alkyl group contains from 1 to 4 carbon atoms; b) 0.01-20% by weight, calculated with respect to the polymer (a), of a carbon black having an average diameter ranging from 10 to 1000 nm and a surface area ranging from 5 to 200 m | 2014-12-18 |
20140371336 | Thermoformable Crosslinked Acrylic - There is provided a thermally reversible admixture comprising (a) an ionically crosslinked polymer matrix comprising at least one (meth)acrylic polymer, a first mole fraction of an acid functional polymer, a second mole fraction of a moiety capable of forming an ionic crosslink with the acid functional polymer, wherein the first mole fraction and the second mole fraction are based on the total number of moles of repeat units in the polymer matrix; and (b) 2 to 50 weight percent microspheres. | 2014-12-18 |
20140371337 | POLYURETHANE FOAM FORMULATION, PRODUCTS AND METHODS - A foam article for use in a seat cushion includes an open cell, polyurethane foam material that includes a base polyol; a crosslinker; an isocyanate; a surfactant; and water, that are reacted together to produce a seat cushion having dynamic and static performance specifications that are better than the performance characteristics for a traditional, high resilient material seat cushion, as well as other seating materials. | 2014-12-18 |
20140371338 | SHELF LIFE OF POLYOL BLENDS CONTAINING HALOGENATED OLEFINS BY ENCAPSULATION OF ACTIVE COMPONENTS - The shelf life of polyurethane polyol pre-blends containing halogenated olefins is extended by encapsulation of active components such as catalysts and/or surfactants. The active component is encapsulated in a crystallizable or thermoplastic polymer. The encapsulated particles have a size of 2,800 microns or less and the active components are not significantly leaked out, particularly in the presence of halogenated olefins. | 2014-12-18 |
20140371339 | POLYPROPYLENE COMPOSITION FOR FOAMING - The present invention relates to a new polypropylene composition for molded articles, such as finished parts for the automotive industry. A composition comprising: (A) from 40 to 85% by weight of a first propylene-based component being selected from propylene homopolymers, propylene copolymers and heterophasic propylene polymer, such first propylene-based component having a flexural modulus higher than 800 MPa; (B) from 5 to 20% by weight of a second propylene-based component being a heterophasic propylene polymer comprising: (B1) from 20 to 90% by weight of a crystalline polypropylene, and (B2) from 10 to 80% by weight of a copolymer of ethylene and at least one C | 2014-12-18 |
20140371340 | Catalytic Membranes And Applications Thereof - In one aspect, catalytic membranes are described herein. In some embodiments, a catalytic membrane comprises a surface functionalized with a polymer, the polymer comprising cellulose solubilization functionalities and acid functionalities for the catalytic hydrolysis of cellulose and/or hemicellulose. | 2014-12-18 |
20140371341 | DENTAL MATERIALS BASED ON COMPOUNDS HAVING DEBONDING-ON-DEMAND PROPERTIES - The invention relates to a dental restorative material which comprises a thermolabile compound of Formula I: | 2014-12-18 |
20140371342 | DENTAL RESTORATIVE MATERIAL - A dental restorative composition is provided that includes a polymerizable resin, a substantially translucent structural filler, a nanofiller having a mean particle size less than 100 nm, and at least one rheology-modifying additive. In one embodiment, the structural filler has a refractive index substantially similar to that of the polymerizable resin, a coarse particle fraction, and a fine particle fraction having a mean particle size greater than 0.1 μm and smaller than the mean particle size of the coarse particle fraction. The relative ratio of the coarse particle fraction to the fine particle fraction is in the range from about 12:1 to about 2:1 by volume, the particle size distribution of each fraction is essentially monomodal, and the D(90) of the fine particle fraction is less than or equal to the D(10) of the coarse particle fraction. | 2014-12-18 |
20140371343 | PAINT WITH ENCAPSULATED SOLID PARTICLES - A paint composition, which comprises a stanchion-encapsulated pigment such as titanium dioxide, can provide enhanced paint quality with reduced cost. | 2014-12-18 |
20140371344 | THERMOPLASTIC (METH)ACRYLATE COPOLYMER, RESIN COMPOSITION COMPRISING SAME, AND MOLDED PRODUCTS THEREOF - Disclosed herein is a thermoplastic (meth)acrylate copolymer, which includes a derivative unit obtained from a monomer mixture including: (A) an aromatic (meth)acrylate having an index of refraction from about 1.580 to about 1.700; and (B) a monofunctional unsaturated monomer. | 2014-12-18 |
20140371345 | RUBBER TIRE COMPOSITION COMPRISING AN AZO-SILANE COUPLING AGENT - A tire rubber composition based on at least one diene elastomer, an inorganic filler as reinforcing filler, a coupling agent providing the bonding between the inorganic filler and the diene elastomer, wherein the coupling agent is an azosilane compound of formula (I): (G | 2014-12-18 |
20140371346 | LOW RIGIDITY TIRE TREAD - Treads and tires having such treads having improved characteristics that break the compromise between wet/dry traction and wear. Such treads may comprise a rubber composition based upon a cross-linkable elastomer composition having a highly unsaturated diene elastomer and between 100 phr and 160 phr of an inorganic reinforcing filler. Embodiments may further include an effective amount of a plasticizing system that includes a plasticizing resin having a glass transition temperature (Tg) of at least 25° C. and a plasticizing liquid. The effective amount of the plasticizer system may be between 60 phr and 130 phr for particular embodiments and is effective in the amount for providing the rubber composition with a shear modulus G* measured at 60° C. of between 0.4 MPa and 1 MPa, Particular embodiments may further include the rubber composition forming the tire tread, to have a glass transition temperature of between −30° C. and 0° C. | 2014-12-18 |
20140371347 | FRICTION MATERIAL - The present invention provides a friction material having compatibility between a high effectiveness and a long life. For that purpose, a titanate compound and a cerium oxide are contained in the friction material, wherein the cerium oxide has an average particle size of 1 μm or less. | 2014-12-18 |
20140371348 | REINFORCING FILLER FOR RUBBER - The present invention describes a reinforcing filler for rubber comprising the synergistic combination of precipitated silica with a pore structure defined by a maximum between 25 nm and 35 nm, a total pore volume between 1.3 cm | 2014-12-18 |